Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more
Kodiak Sciences Inc (KOD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.388x
Based on the latest financial reports, Kodiak Sciences Inc (KOD) has a cash flow conversion efficiency ratio of -1.388x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.88 Million) by net assets ($23.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kodiak Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Kodiak Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kodiak Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kodiak Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gentherm Inc
NASDAQ:THRM
|
0.078x |
|
Sinostone Guangdong Co Ltd
SHE:001212
|
0.012x |
|
Lotte Shopping
KO:023530
|
0.036x |
|
Jinan Acetate Chemical Co Ltd
TW:4763
|
-0.004x |
|
Shanghai Ganglian E Commerce
SHE:300226
|
0.033x |
|
Bank Ina Perdana PT
JK:BINA
|
-0.047x |
|
UNIVEST FINL CORP. DL 5
F:UVE
|
N/A |
|
Horizon Bancorp
NASDAQ:HBNC
|
0.016x |
Annual Cash Flow Conversion Efficiency for Kodiak Sciences Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Kodiak Sciences Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $150.29 Million | $-117.32 Million | -0.781x | -34.56% |
| 2023-12-31 | $265.78 Million | $-154.18 Million | -0.580x | -22.56% |
| 2022-12-31 | $436.17 Million | $-206.46 Million | -0.473x | -72.26% |
| 2021-12-31 | $663.32 Million | $-182.27 Million | -0.275x | -183.50% |
| 2020-12-31 | $860.75 Million | $-83.43 Million | -0.097x | +14.49% |
| 2019-12-31 | $345.36 Million | $-39.15 Million | -0.113x | +66.10% |
| 2018-12-31 | $86.83 Million | $-29.03 Million | -0.334x | -230.17% |
| 2017-12-31 | $-68.74 Million | $-17.66 Million | 0.257x | -34.24% |
| 2016-12-31 | $-41.08 Million | $-16.05 Million | 0.391x | -- |